Corbus Pharmaceuticals Holdings (CRBP) EBITDA Margin (2015 - 2021)

Corbus Pharmaceuticals Holdings has reported EBITDA Margin for 7 years, with the latest figure at 14257.07% in Q3 2021.

• On a quarterly basis, EBITDA Margin fell 1149635.0% year-over-year to 14257.07% in Q3 2021; TTM through Jun 2022 was 45961.32%, a 4271049.0% decrease from a year earlier, with the FY2021 full-year figure at 6350.09%, down 323088.0% from the prior year.
• EBITDA Margin was 14257.07% for Q3 2021 at Corbus Pharmaceuticals Holdings, down from 12230.01% in the prior quarter.
• The five-year high for EBITDA Margin was 5.86% in Q2 2019, with the low at 14257.07% in Q3 2021.
• Average EBITDA Margin over 5 years is 3430.06%, with a median of 1429.2% recorded in 2018.
• The sharpest annual moves came in 2019 and 2020: EBITDA Margin jumped 145772 bps in 2019, then sank 1332495 bps in 2020.
• Over 5 years, EBITDA Margin stood at 873.63% in 2017, then fell by 4 bps to 912.72% in 2018, then dropped by 16 bps to 1056.54% in 2019, then plunged by 199 bps to 3161.99% in 2020, then tumbled by 351 bps to 14257.07% in 2021.
• The last three EBITDA Margin figures came in at 14257.07% (Q3 2021), 12230.01% (Q2 2021), and 2379.38% (Q1 2021), per Business Quant data.